|
1
|
Baigrie D and Nookala V: Bullous
pemphigoid. StatPearls (Internet). StatPearls Publishing, Treasure
Island, FL, 2022.
|
|
2
|
LEVER WF: Pemphigus. Medicine (Baltimore).
32:1–123. 1953.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jordan RE, Day NK, Sams WM Jr and Good RA:
The complement system in bullous pemphigoid. I. Complement and
component levels in sera and blister fluids. J Clin Invest.
52:1207–1214. 1973.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cole C, Vinay K, Borradori L and Amber KT:
Insights into the pathogenesis of bullous pemphigoid: The role of
complement-independent mechanisms. Front Immunol.
13(912876)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sadik CD and Schmidt E: Resolution in
bullous pemphigoid. Semin Immunopathol. 41:645–654. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tabatabaei-Panah PS, Moravvej H, Aghaei S,
Akbari M, Rajabi S, Kia A, Ebrahimi E, Sadaf Z, Atoon A, Behravesh
N, et al: TH17/IL23 cytokine gene polymorphisms in bullous
pemphigoid. Mol Genet Genomic Med. 8(e1519)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Genovese G, Di Zenzo G, Cozzani E, Berti
E, Cugno M and Marzano AV: New insights into the pathogenesis of
bullous pemphigoid: 2019 update. Front Immunol.
10(1506)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kasperkiewicz M, Zillikens D and Schmidt
E: Pemphigoid diseases: Pathogenesis, diagnosis, and treatment.
Autoimmunity. 45:55–70. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Verbeek JS, Hirose S and Nishimura H: The
complex association of FcγRIIb With autoimmune susceptibility.
Front Immunol. 10(2061)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bournazos S and Ravetch JV: Fcγ receptor
pathways during active and passive immunization. Immunol Rev.
268:88–103. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ujiie H, Shibaki A, Nishie W, Sawamura D,
Wang G, Tateishi Y, Li Q, Moriuchi R, Qiao H, Nakamura H, et al: A
novel active mouse model for bullous pemphigoid targeting humanized
pathogenic antigen. J Immunol. 184:2166–2174. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Franziska SK, Beckmann T, Nimmerjahn F,
Ishiko A, Collin M, Köhl J, Goletz S, Zillikens D, Ludwig R and
Schmidt E: Fcγ receptors III and IV mediate tissue destruction in a
novel adult mouse model of bullous pemphigoid. Am J Pathol.
184:2185–2196. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Heimbach L, Li N, Diaz A and Liu Z:
Experimental animal models of bullous pemphigoid. G Ital Dermatol
Venereol. 144:423–431. 2009.PubMed/NCBI
|
|
14
|
Hiroyasu S, Turner CT, Richardson KC and
Granville DJ: Proteases in pemphigoid diseases. Front Immunol.
10(1454)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu Y, Peng L, Li L, Liu C, Hu X, Xiao S
and Xia Y: TWEAK/Fn14 activation contributes to the pathogenesis of
bullous pemphigoid. J Invest Dermatol. 137:1512–1522.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Karashima T, Hachisuka H, Okubo K and
Sasai Y: Epidermal keratinocytes of bullous pemphigoid express
intercellular adhesion molecule-1 (ICAM-1). J Dermatol. 19:82–86.
1992.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kaminska R, Naukkarinen A, Glinski W,
Horsmanheimo M and Harvima IT: Mast cells in developing
subepidermal bullous diseases: Emphasis on tryptase, chymase and
protease inhibitors. Acta Derm Venereol. 79:351–355.
1999.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Maronese CA, Caproni M, Moltrasio C,
Genovese G, Vezzoli P, Sena P, Previtali G, Cozzani E, Gasparini G,
Parodi A, et al: Bullous pemphigoid associated with COVID-19
vaccines: An Italian multicentre study. Front Med (Lausanne).
9(841506)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Aronson JK: Influenza vaccine. In:
Meyler's Side Effects of Drugs: The International Encyclopedia of
Adverse Drug Reactions and Interactions. Vol 7. 16th edition.
Elsevier, pp98-106, 2016.
|
|
20
|
Modeste AB, Cordel N, Courville P, Gilbert
D, Lauret P and Joly P: Bullous pemphigoid induced by
spironolactone. Ann Dermatol Venereol. 129:56–58. 2002.PubMed/NCBI(In French).
|
|
21
|
Warner C, Kwak Y, Glover MHB and Davis LS:
Bullous pemphigoid induced by hydrochlorothiazide therapy. J Drug
Dermatol. 13:360–362. 2014.PubMed/NCBI
|
|
22
|
Verheyden MJ, Bilgic A and Murrell DF: A
systematic review of drug-induced pemphigoid. Acta Derm Venereol.
100(adv00224)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wofford J, Patel M, Readinger A and Menter
A: Widespread dermal ulcerations and bullae. Proc (Bayl Univ Med
Cent). 25:155–158. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Griffiths C, Barker J, Bleiker T, Chalmers
R and Creamer D: Immunobullous diseases. In: Rook's Textbook of
Dermatology. Vol 2. 9th edition. Wiley Blackwell Publishers, part
4, chapter 50, 2016.
|
|
25
|
Cohen PR: Dyshidrosiform bullous
pemphigoid. Medicina (Kaunas). 57(398)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Deotto ML, Spiller A, Sernicola A and
Alaibac M: Bullous pemphigoid: An immune disorder related to aging
(Review). Exp Ther Med. 23(50)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Niebel D, Wilsmann-Theis D, Bieber T,
Berneburg M and Wenzel J: Braegelmann C: Bullous pemphigoid in
patients receiving immune-checkpoint inhibitors and psoriatic
patients-focus on clinical and histopathological variation.
Dermatopathology (Basel). 9:60–81. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tsiogka A, Bauer JW and Patsatsi A:
Bullous pemphigoid associated with anti-programmed cell death
protein 1 and anti-programmed cell death ligand 1 therapy: A review
of the literature. Acta Derm Venereol. 101(adv00377)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zheng Q, Ma Y, Shen F, Wang Q, Song X,
Jiang W and Xie S: Case of bullous pemphigoid induced by apatinib
mesylate. Br J Clin Pharmacol. 87:2158–2159. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pruessmann J, Pruessmann W, Holtsche MM,
Linnemann B, Hammers CM, van Beek N, Zillikens D, Schmidt E and
Sadik CD: Immunomodulator galectin-9 is increased in blood and skin
of patients with bullous pemphigoid. Acta Derm Venereol.
101(adv00419)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kridin K, Schonmann Y, Weinstein O,
Schmidt E, Ludwig RJ and Cohen AD: The risk of COVID-19 in patients
with bullous pemphigoid and pemphigus: A population-based cohort
study. J Am Acad Dermatol. 85:79–87. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kim YB, Choi HS, Cho HK and Seo GW:
Diagnosis and treatment of bullous pemphigoid that developed twice
after total knee replacement arthroplasty: A case report. BMC
Musculoskelet Disord. 22(118)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Liu SD, Chen WT and Chi CC: Association
between medication use and bullous pemphigoid: A systematic review
and meta-analysis. JAMA Dermatol. 156:891–900. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tasanen K, Varpuluoma O and Nishie W:
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Front Immunol. 10(1238)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kridin K and Bergman R: Association of
bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in
patients with diabetes: Estimating the risk of the new agents and
characterizing the patients. JAMA Dermatol. 154:1152–1158.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hoffer S, Hategan A and Bourgeois JA: .
Amantadine-associated bullous pemphigoid. J Clin Psychopharmacol.
38:394–395. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hoffmann S, Berneburg M and Schreml S:
Bullous pemphigoid associated with adalimumab therapy in a patient
with ulcerative colitis. Case Rep Dermatol. 10:145–148.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jang H, Jin YJ, Yoon CH, Kim CW and Kim L:
Bullous pemphigoid associated with chronic hepatitis C virus
infection in a hepatitis B virus endemic area: A case report.
Medicine (Baltimore). 97(e0377)2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Flamm A, Sachdev S and Dufresne F:
Gabapentin-induced bullous pemphigoid. J Am Osteopath Assoc.
117:191–193. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mendonça FM, Martín-Gutierrez FJ,
Ríos-Martín JJ and Camacho-Martinez F: Three cases of bullous
pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one
due to linagliptin. Dermatology. 232:249–253. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Williams G, Goodwin R and Hughes D:
Amlodipine as a cause of mucous membrane pemphigoid: First report
of amlodipine as a causative agent in MMP. Eye (Lond).
27(1425)2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Park KY, Kim BJ and Kim MN:
Amlodipine-associated bullous pemphigoid with erythema
multiforme-like clinical features. Int J Dermatol. 50:637–639.
2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Monteagudo B, Heras C, Bouza P, Almagro M,
Álvarez JC and Cacharrón JM: Bullous pemphigoid after treatment
with amlodipine. Med Cutan Iber Lat Am. 36:308–311. 2008.
|
|
44
|
Mukhopadhyay AK: Two eponyms in the
histopathology of lichen planus: Creation and confusion. Indian J
Dermatol Venereol Leprol. 88:270–273. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yang M, Wu H, Zhao M, Chang C and Lu Q:
The pathogenesis of bullous skin diseases. J Transl Autoimmun.
2(100014)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mozafari N, Ganji R and Toossi P: A rare
new presentation of pemphigus vulgaris. Clin Case Rep.
10(e5979)2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Criado PR, Criado RF, Maruta CW and Reis
VM: Chronic urticaria in adults: State-of-the-art in the new
millennium. An Bras Dermatol. 90:74–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kaur S and Handa S: Erythema multiforme
following vaccination in an infant. Indian J Dermatol Venereol
Leprol. 74:251–253. 2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Feliciani C, Joly P, Jonkman MF, Zambruno
G, Zillikens D, Ioannides D, Kowalewski C, Jedlickova H, Kárpáti S,
Marinovic B, et al: Management of bullous pemphigoid: The european
dermatology forum consensus in collaboration with the european
academy of dermatology and venereology. Br J Dermatol. 172:867–877.
2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Clapé A, Muller C, Gatouillat G, Le Jan S,
Barbe C, Pham BN, Antonicelli F and Bernard P: Mucosal involvement
in bullous pemphigoid is mostly associated with disease severity
and to absence of Anti-BP230 autoantibody. Front Immunol.
9(479)2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wijayanti A, Zhao CY, Boettiger D, Chiang
YZ, Ishii N, Hashimoto T and Murrell DF: The reliability, validity
and responsiveness of two disease scores (BPDAI and ABSIS) for
bullous pemphigoid: Which one to use? Acta Derm Venereol. 97:24–31.
2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Pratasava V, Sahni VN, Suresh A, Huang S,
Are A, Hsu S and Motaparthi K: Bullous pemphigoid and other
pemphigoid dermatoses. Medicina (Kaunas). 57(1061)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sebaratnam DF, Okawa J, Payne A, Murrell
DF and Werth VP: Reliability of the autoimmune bullous disease
quality of life (ABQOL) questionnaire in the USA. Qual Life Res.
24:2257–2260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kouris A, Platsidaki E, Christodoulou C,
Armyra K, Korkoliakou P, Stefanaki C, Tsatovidou R, Rigopoulos D
and Kontochristopoulos G: Quality of life, depression, anxiety and
loneliness in patients with bullous pemphigoid. A case control
study. An Bras Dermatol. 91:601–603. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Giusti D, Gatouillat G, Le Jan S, Plée J,
Bernard P, Antonicelli F and Pham BN: Eosinophil cationic protein
(ECP), a predictive marker of bullous pemphigoid severity and
outcome. Sci Rep. 7(4833)2017.PubMed/NCBI View Article : Google Scholar
|
